NICE 'conditional approvals' to replace England's Cancer Drugs Fund
This article was originally published in Scrip
A new "managed access fund" for financing oncology drugs conditionally approved by NICE could provide a proper long-term remedy to England's poor uptake of oncology products if it can replace the Cancer Drugs Fund, something that has become a soggy sticking plaster. But although the plans may offer companies hope of market access for future drugs, there is still uncertainty over what will happen to patients and drugs failed by the current system, like Eisai's Halaven.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.